Proteomedix raises €4.4M Seed round
16 August 2016· Zurich, Switzerland· health, biotech, diagnostics, oncology, b2b, pure_software
The new funds will enable ProteoMediX to continue the development of its lead product for prostate cancer diagnosis into a final CE-certified IVD product and gather additional clinical data.
Investors
LeadAltos Venture
Also participating
Zürcher Kantonalbank
About Proteomedix
Stage
Series B
Headquarters
Zurich, Switzerland
Founded
2010
Team Size
6–20
Sectors
healthbiotechdiagnosticsoncologyb2bpure_software